missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Chemicals
  4. Organic compounds
  5. Organonitrogen Compounds
  6. N-organohydroxylamines
  7. 18036012

MeBIO, Tocris Bioscience™
GREENER_CHOICE

Product Code. 18036012
Click to view available options
Quantity:
10 mg
Unit Size:
10mg
This item is not returnable. View return policy

Product Code. 18036012

Brand: Tocris Bioscience 3873/10

Please to purchase this item. Need a web account? Register with us today!

This item is currently unavailable or has been discontinued.
View the product page for possible alternatives.
 View alternative products

This item is not returnable. View return policy

Description

Inactive analog of BIO (Cat. No. 3194)

Control analog of 6-bromoindirubin-3'-oxime ( BIO ). Displays minimal activity against CDK1/Cyclin B, GSK-3 α/β, and CDK5/p25 (IC50 values are 92.0, 44-100 and >100 μM respectively). Aryl hydrocarbon receptor (AhR) agonist; causes redistribution of AhR to the nucleus.

Active Analog also available.

TRUSTED_SUSTAINABILITY

Specifications

CAS 667463-95-8
Molecular Formula C17H12BrN3O2
Quantity 10 mg
Synonym mebio, gsk-3 inhibitor ix, control, mebio
InChI Key WWVVQXIBSZPELF-JQIJEIRASA-N
SMILES CN1C2=C(C=CC(=C2)Br)C(=C3C(=C4C=CC=CC4=N3)NO)C1=O
IUPAC Name (3E)-6-bromo-3-[3-(hydroxyamino)indol-2-ylidene]-1-methylindol-2-one
Molecular Weight (g/mol) 370.206
PubChem CID 73952600
Formula Weight 370.2
Percent Purity >99%
Chemical Name or Material MeBIO
Show More Show Less
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.